The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform

Henning T. Mouridsen - One of the best experts on this subject based on the ideXlab platform.

  • Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial
    Breast Cancer Research and Treatment, 2006
    Co-Authors: Mogens Groenvold, Peter M. Fayers, Morten Aagaard Petersen, Henning T. Mouridsen
    Abstract:

    Background Ovarian ablation is an effective adjuvant therapy for primary breast cancer but little is known about its quality of life impact relative to the more widely used adjuvant Chemotherapy. This randomized study compared quality of life outcomes of adjuvant ovarian ablation versus cyclophosphamide, methotrexate, fluoracil (CMF) Chemotherapy. Methods The Danish Breast Cancer Cooperative Group (DBCG) trial 89-b randomized premenopausal patients with receptor-positive, primary breast cancer between nine cycles of CMF Chemotherapy given every 3 weeks and ovarian ablation by oophorectomy. In total, 317 randomized patients were invited to take part in a longitudinal quality of life study with assessments at 1, 3, 5, 9, 15, and 24 months after randomization. The questionnaire included the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale, and additional items assessing potential symptoms not included in the standard instruments. Results After 2 years, 260 women were alive and recurrence-free, and 196 of these (75%) had completed all six questionnaires. Overall, patients in the Chemotherapy group had more symptomatology at the first three assessments (i.e., during the 6 months treatment period), except for hot flushes/sweats. There were few differences between groups at later assessments. In Chemotherapy patients, the likelihood of preserving ovarian function decreased steeply with increasing age. CMF Chemotherapy and ovarian ablation have similar impact on recurrence and survival. Conclusion Chemotherapy had more negative impact on health-related quality of life but preserved ovarian function in some younger patients.

  • Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
    Breast cancer research and treatment, 2006
    Co-Authors: Mogens Groenvold, Peter M. Fayers, Morten Aagaard Petersen, Henning T. Mouridsen
    Abstract:

    Background Ovarian ablation is an effective adjuvant therapy for primary breast cancer but little is known about its quality of life impact relative to the more widely used adjuvant Chemotherapy. This randomized study compared quality of life outcomes of adjuvant ovarian ablation versus cyclophosphamide, methotrexate, fluoracil (CMF) Chemotherapy.

Walter Jonat - One of the best experts on this subject based on the ideXlab platform.

  • CMF versus goserelin as adjuvant therapy for node negative hormone receptor positive breast cancer in premenopausal patients a randomised trial gabg trial iv a 93
    European Journal of Cancer, 2006
    Co-Authors: Gunter Von Minckwitz, Erika Graf, M Geberth, K Brunnert, Bernd Gerber, S Vescia, Walter Jonat, B. Conrad, Wolfgang Eiermann, Jorg Wollert
    Abstract:

    Abstract Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer. Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) Chemotherapy ( n  = 378) or goserelin every 28 d for 2 years ( n  = 393). During a median follow-up of 4.9 years, 123 events were observed. The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2). Forty-two (23 versus 19) deaths of any cause occurred. The estimated adjusted hazard ratio for goserelin versus CMF (intention-to-treat analysis) was 0.79 (95% CI = 0.54–1.14; P  = 0.19). It is concluded that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer.

  • survival analyses from the zebra study goserelin zoladex versus CMF in premenopausal women with node positive breast cancer
    European Journal of Cancer, 2003
    Co-Authors: M. Kaufmann, Jack Cuzick, M Namer, J C J M De Haes, Walter Jonat, Roger W. Blamey, Ignac Fogelman, Martin Schumacher, Willi Sauerbrei
    Abstract:

    The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) Chemotherapy in pre-/perimenopausal women with node-positive early breast cancer. The results of disease-free survival (DFS) analyses have already been published. Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years. In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS. This updated analysis has demonstrated that the two treatments are also equivalent for distant disease-free survival (DDFS). In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS. This follow-up analysis confirms the previously reported outcomes from the ZEBRA trial and demonstrates that goserelin offers an effective alternative to CMF Chemotherapy for adjuvant therapy of premenopausal patients with ER-positive, node-positive early breast cancer.

  • goserelin versus cyclophosphamide methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer the zoladex early breast cancer research association study
    Journal of Clinical Oncology, 2002
    Co-Authors: Walter Jonat, Jack Cuzick, M Namer, J C J M De Haes, A De Matteis, Roger W. Blamey, Willi Sauerbrei, Ignac Fogelman, M. Kaufmann, Alan L. Stewart
    Abstract:

    PURPOSE: Current adjuvant therapies have improved survival for premenopausal patients with breast cancer but may have short-term toxic effects and long-term effects associated with premature menopause. PATIENTS AND METHODS: The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) Chemotherapy (six 28-day cycles; n = 823) for adjuvant treatment in premenopausal patients with node-positive breast cancer. RESULTS: Analysis was performed when 684 events had been achieved, and the median follow-up was 6 years. A significant interaction between treatment and estrogen receptor (ER) status was found (P = .0016). In ER-positive patients (approximately 74%), goserelin was equivalent to CMF for disease-free survival (DFS) (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.84 to 1.20). In ER-negative patients, goserelin was inferior to CMF for DFS (HR, ...

Mogens Groenvold - One of the best experts on this subject based on the ideXlab platform.

  • Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial
    Breast Cancer Research and Treatment, 2006
    Co-Authors: Mogens Groenvold, Peter M. Fayers, Morten Aagaard Petersen, Henning T. Mouridsen
    Abstract:

    Background Ovarian ablation is an effective adjuvant therapy for primary breast cancer but little is known about its quality of life impact relative to the more widely used adjuvant Chemotherapy. This randomized study compared quality of life outcomes of adjuvant ovarian ablation versus cyclophosphamide, methotrexate, fluoracil (CMF) Chemotherapy. Methods The Danish Breast Cancer Cooperative Group (DBCG) trial 89-b randomized premenopausal patients with receptor-positive, primary breast cancer between nine cycles of CMF Chemotherapy given every 3 weeks and ovarian ablation by oophorectomy. In total, 317 randomized patients were invited to take part in a longitudinal quality of life study with assessments at 1, 3, 5, 9, 15, and 24 months after randomization. The questionnaire included the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale, and additional items assessing potential symptoms not included in the standard instruments. Results After 2 years, 260 women were alive and recurrence-free, and 196 of these (75%) had completed all six questionnaires. Overall, patients in the Chemotherapy group had more symptomatology at the first three assessments (i.e., during the 6 months treatment period), except for hot flushes/sweats. There were few differences between groups at later assessments. In Chemotherapy patients, the likelihood of preserving ovarian function decreased steeply with increasing age. CMF Chemotherapy and ovarian ablation have similar impact on recurrence and survival. Conclusion Chemotherapy had more negative impact on health-related quality of life but preserved ovarian function in some younger patients.

  • Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
    Breast cancer research and treatment, 2006
    Co-Authors: Mogens Groenvold, Peter M. Fayers, Morten Aagaard Petersen, Henning T. Mouridsen
    Abstract:

    Background Ovarian ablation is an effective adjuvant therapy for primary breast cancer but little is known about its quality of life impact relative to the more widely used adjuvant Chemotherapy. This randomized study compared quality of life outcomes of adjuvant ovarian ablation versus cyclophosphamide, methotrexate, fluoracil (CMF) Chemotherapy.

Willi Sauerbrei - One of the best experts on this subject based on the ideXlab platform.

  • survival analyses from the zebra study goserelin zoladex versus CMF in premenopausal women with node positive breast cancer
    European Journal of Cancer, 2003
    Co-Authors: M. Kaufmann, Jack Cuzick, M Namer, J C J M De Haes, Walter Jonat, Roger W. Blamey, Ignac Fogelman, Martin Schumacher, Willi Sauerbrei
    Abstract:

    The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) Chemotherapy in pre-/perimenopausal women with node-positive early breast cancer. The results of disease-free survival (DFS) analyses have already been published. Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years. In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS. This updated analysis has demonstrated that the two treatments are also equivalent for distant disease-free survival (DDFS). In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS. This follow-up analysis confirms the previously reported outcomes from the ZEBRA trial and demonstrates that goserelin offers an effective alternative to CMF Chemotherapy for adjuvant therapy of premenopausal patients with ER-positive, node-positive early breast cancer.

  • goserelin versus cyclophosphamide methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer the zoladex early breast cancer research association study
    Journal of Clinical Oncology, 2002
    Co-Authors: Walter Jonat, Jack Cuzick, M Namer, J C J M De Haes, A De Matteis, Roger W. Blamey, Willi Sauerbrei, Ignac Fogelman, M. Kaufmann, Alan L. Stewart
    Abstract:

    PURPOSE: Current adjuvant therapies have improved survival for premenopausal patients with breast cancer but may have short-term toxic effects and long-term effects associated with premature menopause. PATIENTS AND METHODS: The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) Chemotherapy (six 28-day cycles; n = 823) for adjuvant treatment in premenopausal patients with node-positive breast cancer. RESULTS: Analysis was performed when 684 events had been achieved, and the median follow-up was 6 years. A significant interaction between treatment and estrogen receptor (ER) status was found (P = .0016). In ER-positive patients (approximately 74%), goserelin was equivalent to CMF for disease-free survival (DFS) (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.84 to 1.20). In ER-negative patients, goserelin was inferior to CMF for DFS (HR, ...

Jorg Wollert - One of the best experts on this subject based on the ideXlab platform.

  • CMF versus goserelin as adjuvant therapy for node negative hormone receptor positive breast cancer in premenopausal patients a randomised trial gabg trial iv a 93
    European Journal of Cancer, 2006
    Co-Authors: Gunter Von Minckwitz, Erika Graf, M Geberth, K Brunnert, Bernd Gerber, S Vescia, Walter Jonat, B. Conrad, Wolfgang Eiermann, Jorg Wollert
    Abstract:

    Abstract Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer. Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) Chemotherapy ( n  = 378) or goserelin every 28 d for 2 years ( n  = 393). During a median follow-up of 4.9 years, 123 events were observed. The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2). Forty-two (23 versus 19) deaths of any cause occurred. The estimated adjusted hazard ratio for goserelin versus CMF (intention-to-treat analysis) was 0.79 (95% CI = 0.54–1.14; P  = 0.19). It is concluded that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer.